Associated Labs/Orgs
Description
AMX0035 is an investigational therapy—an oral coformulation of 2 active compounds, sodium phenylbutyrate and taurursodiol. Amylyx is currently exploring the potential of AMX0035 as a treatment option for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome.
Funding
$202.2M
Invasive / Non-invasive / Semi-invasive
Non-invasive
New/Existing Tech
Tech used (specifics)
Pharmaceutical
Techs Used
Year Founded
2014